Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 22 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/29/2008 First Published: 7/1/1996


1.		Phase II/III Randomized Study of First-Line Hormonal Therapy With Exemestane Versus Tamoxifen in Postmenopausal Women With Locally Recurrent or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Postmenopausal				Pharmaceutical / Industry				EORTC-10951 PHARMACIA-EORTC-10951, NCT00002777

Last Modified: 3/26/2008 First Published: 9/1/1998


2.		Phase III Randomized Study of Exemestane Versus Tamoxifen in Postmenopausal Women With Primary Breast Cancer Who Have Already Received 2-3 Years of Adjuvant Tamoxifen After Potentially Curable Surgery

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Postmenopausal								ICCG-96OEXE031-C1396-BIG9702 EORTC-10967, FRE-FNCLCC-PACS02/96OEXE031, EU-20013, EU-99002, ICCG-BIG-97/02, NCT00003418

Last Modified: 3/14/2008 First Published: 5/1/2001


3.		Phase III Randomized Study of Exemestane in Postmenopausal Women With Resected Stage I, II, or IIIA Breast Cancer Who Have Completed Five Years of Tamoxifen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Postmenopausal				NCI				NSABP-B-33 ECOG-NSABP-B-33, NCT00016432

Last Modified: 5/18/2007 First Published: 3/1/2002


4.		Phase III Randomized Study of Adjuvant Exemestane Versus Adjuvant Tamoxifen in Postmenopausal Women With Early Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Other				CRC-TU-TEAM EU-20149, ISRCTN75225940, NCT00032136

Last Modified: 11/3/2008 First Published: 7/26/2003


5.		Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole in Postmenopausal Women With Receptor-Positive Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Postmenopausal				NCI, Other				CAN-NCIC-MA27 (COMPANION) NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, NCIC-MA.27, NCT00066573, IBCSG-30-04, EUDRACT-2005-001893-28, MA27

Last Modified: 10/23/2008 First Published: 7/26/2003


6.		Phase III Randomized Study of Ovarian-Function Suppression and Tamoxifen or Exemestane With Versus Without Adjuvant Chemotherapy in Premenopausal Women With Endocrine-Responsive Resected Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Premenopausal				NCI				IBCSG-26-02 BIG-4-02, NABCI-IBCSG-26-02, EU-20401, NCT00066807, EUDRACT-2005-002626-59


7.		The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Postmenopausal				Pharmaceutical / Industry				9238IL/0048 EFECT, NCT00065325


8.		Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed by Exemestane

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				50 and over				Pharmaceutical / Industry				971-ONC-0028-081 A5991012, NCT00036270


9.		Randomized Trial Of Exemestane Vs. Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				30 and over				Pharmaceutical / Industry				96-OEXE-031 NCT00038467

Last Modified: 9/26/2007 First Published: 2/16/2007


10.		Phase III Randomized Study of Adjuvant Exemestane Versus Anastrozole in Postmenopausal Women With Hormone Receptor-Positive Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				45 and over				NCI				CAN-NCIC-MA27 (NON-COMPANION) NCIC-MA27 (NON-COMPANION), IBCSG-30-04, NCT00438529, MA27

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute